Stock Traders Purchase Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL)

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) saw unusually large options trading activity on Monday. Stock traders acquired 2,496 call options on the stock. This is an increase of approximately 476% compared to the average daily volume of 433 call options.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.73 on Tuesday. The firm has a market capitalization of $460.42 million, a P/E ratio of -2.08 and a beta of 1.98. The business has a 50 day simple moving average of $1.58 and a 200 day simple moving average of $1.55. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $2.70.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AUTL. Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright assumed coverage on Autolus Therapeutics in a research report on Tuesday, February 17th. They set a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC reduced their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Finally, Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Mak Capital One LLC increased its stake in shares of Autolus Therapeutics by 15.3% in the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares during the period. Armistice Capital LLC grew its holdings in Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,900,000 shares in the last quarter. TFG Asset Management GP Ltd increased its position in Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares during the period. Schroder Investment Management Group raised its stake in Autolus Therapeutics by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after acquiring an additional 1,056,092 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after acquiring an additional 1,054,458 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.